Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.
Recent innovations in breast cancer include new findings on financial outcomes, the use of antibody drug conjugates, and combining targeted treatments, explains Dawn Klemow, MD, assistant clinical professor, The University of Texas Southwestern Medical Center.
Klemow is one of the panelists who will present on these research topics at the Institute for Value-Based Medicine® event, "Evaluating Value in Cancer Care: Dallas."
This transcript was lightly edited for clarity.
Transcript
When evaluating new treatments for breast cancer, what markers of success beyond traditional end points help determine their impact on patient outcomes and value in care?
Well, of course, progression-free survival and overall survival are still the gold standards of knowing how well a treatment is going to help these women, but there are other factors to consider. We need to look at treatments that have less toxicity, better ease of administration, require less monitoring, are affordable. I think those aspects of care are also very important when evaluating how well a treatment is going to help women.
Antibody drug conjugates have become a critical tool in breast cancer treatment. How do you prioritize targeted therapies in HER2-low or ultralow breast cancer, especially when multiple options are available?
The DESTINY-04 [DESTINY-Breast04; NCT03734029] trial first came out looking at the benefit of antibody drug conjugates in HER2-low disease, showing basically a doubling of progression-free survival over doctors’ chemotherapy choice, and then more recently, DESTINY-06 [DESTINY-Breast06; NCT04494425] showing that there's an equal benefit in HER2-ultralow. The issue with HER2-ultralow is still we have to get our pathologist to define it for us, so we know which patients would benefit from drugs like Enhertu [fam-trastuzumab - deruxtecan-nxki; Daiichi-Sankyo/AstraZeneca]. As far as prioritizing, for me, if a patient has triple-negative disease that’s ultralow, I'll usually use Trodelvy [sacituzumab govitecan-hziy; Gilead]. I think there's more data with Trodelvy for triple-negative, but for women who are endocrine sensitive, I will use Enhertu.
What emerging areas of research in metastatic breast cancer do you see as most likely to advance personalized treatment strategies, and how can providers prepare to integrate these advancements?
I think the advancements are really going to be in combining targeted treatments; adding CDK4/6 inhibitors to HER2-positive disease. We just had a positive trial showing that there's a benefit to adding Ibrance [palbociclib; Novartis] with HER2-targeted treatment. I think the way things are going is looking at combinations of unique molecules to better perform than, again, standard chemotherapy or hormonal therapies that we've traditionally used. I think that's going to be the wave of the future, and it's going to require oncologists to have a very good understanding of next-generation sequencing and the information that these tests can provide.
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Dermatologists Advocating for Inclusive Hair Loss Research and Treatment in the African Diaspora
March 26th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, advocates for increased funding and education to address hair loss disparities within the African diaspora, emphasizing the need for culturally sensitive treatment and research.
Read More
Strategies for Improving Patient Access to Dermatology Care
March 22nd 2025Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.
Read More